Showing results (31-40 of 57) with videos related to
Sort By:
Pageof 6
Oncotarget|July 14, 2016
Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort studyQian Li, Huiqin Jiang, Hong Li, et al.BMC Medicine|April 6, 2022
Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trialZhaoqing Tang, Yan Wang, Yiyi Yu, et al.Oncotarget|April 30, 2016
FOXO3a promotes gastric cancer cell migration and invasion through the induction of cathepsin LShan Yu, Yiyi Yu, Wen Zhang, et al.Cell Reports. Medicine|February 1, 2023
Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancerZhaoqing Tang, Yuan Gu, Zhongyi Shi, et al.Cancer Medicine|November 5, 2024
Transarterial Infusion Chemotherapy and Embolization for Patients With Unresectable Advanced Cancer of Stomach or Gastroesophageal Junction: A Retrospective StudyLingqiang Min, Zheng Liu, Bo Zhou, et al.International Journal of Clinical and Experimental Pathology|June 6, 2015
Activation of FOXO3a suggests good prognosis of patients with radically resected gastric cancerShan Yu, Yiyi Yu, Yihong Sun, et al.Journal of Cellular and Molecular Medicine|March 27, 2019
5-Hydroxymethylcytosine profiling from genomic and cell-free DNA for colorectal cancers patientsPingting Gao, Shengli Lin, Mingyan Cai, et al.BMC Cancer|April 4, 2023
Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)Yuehong Cui, Yiyi Yu, Song Zheng, et al.Oncotarget|November 9, 2016
FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-MycYiyi Yu, Mengzhou Guo, Ye Wei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2020
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for <i>RAS</i> Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled TrialWentao Tang, Li Ren, Tianshu Liu, et al.Pageof 6